Sept 14 (Reuters) - Hong Kong stocks ended higher on Monday
tracking a global rally on fresh coronavirus vaccine hopes,
while investors also awaited the U.S. Federal Reserve's policy
meeting later this week for monetary policy outlook cues in the
world's largest economy.
** AstraZeneca said on the weekend it has resumed
British clinical trials of its COVID-19 vaccine, one of the most
advanced in development, after getting the green light from
** Governments around the world are desperate for a vaccine to
help end the pandemic, which has caused more than 900,000 deaths
and a global economic turmoil. The World Health Organization
(WHO) had flagged AstraZeneca's vaccine candidate as the most
** At the close of trade, the Hang Seng index was up
136.97 points or 0.56% at 24,640.28. The Hang Seng China
Enterprises index rose 0.56% to 9,806.64.
** The sub-index of the Hang Seng tracking energy shares
, while the IT sector rose 1.66%, the
financial sector was flat and the property sector rose
** The top gainer on the Hang Seng was China Unicom Hong Kong
Ltd, which gained 5.37%, while the biggest loser was
Geely Automobile Holdings Ltd, which fell 1.48%.
** China's main Shanghai Composite index closed up 0.57%
at 3,278.81 points, while the blue-chip CSI300 index
ended up 0.51%.
** China stocks finished higher on Monday with Shanghai's
Nasdaq-style STAR Market leading gains after securities
regulator approved the first batch of exchange-traded funds
(ETFs), which are expected to draw fresh funds towards the
** Around the region, MSCI's Asia ex-Japan stock index
was firmer by 0.47%, while Japan's Nikkei index
closed up 0.65%.
(Reporting by Winni Zhou and Andrew Galbraith; Editing by